Pfizer Launches Final Study Pertaining to COVID Drug That’s Suspiciously Similar To ‘Horse Paste’
Coincidentally (or not), Pfizer’s medication shares at least one mechanism associated with action as Ivermectin
Another piece US anti-Ivermectin puzzle may have emerged. Upon Monday, Pfizer announced that it might be launching an accelerated Stage 2/3 trial for a COVID prophylactic pill designed to defend against COVID in those might have come in contact with the disease.
Coincidentally (or not), Pfizer’s drug shares at least one system of action as Ivermectin – an anti-parasitic used in human beings for decades, which functions since a protease inhibitor against Covid-19, which researchers speculate “ could be the biophysical basis behind its antiviral efficiency. ”
Lo and behold, Pfizer’s new drug – which some have jokingly called “ Pfizermectin, ” is certainly described by the pharmaceutical giant as a “ potent protease inhibitor. ”
Since Zero Hedge readers might recognize, that’s exactly what ivermectin, the prophylactic used for a number of reasons in both humans and animals, does. And as opposed to Pfizer’s experimental drug, ivermectin already may possess saved hundreds of thousands of life from India to Brazilian.
We all aren’t the only ones to get put this together, because twitter users have commented over the similarities. The timing – which coincides with the whole “ horse dewormer ” smear campaign – just seems unusual.
The likeness between Pfizer’s upcoming providing and Ivermectin has not gone unnoticed .
But Pfizer, Moderna and their professionals have already shown the world using their actions that they see COVID as “ manna through heaven” – to quotation legendary defense attorney Ashton Cochran – a brand new ‘ profit center’ that will keep shareholders in butter brickle, especially since the companies have quietly raised prices on their vaccines.
But since a large portion of the American market has turned down the vaccines, Pfizer requirements another medication that can be used to treat them as well (otherwise, the organization is missing out on nearly one-third of the American market).
According to Reuters , Pfizer said on Monday it has “ started a large study assessment its investigational oral antiviral drug for the prevention of COVID-19 infection among those who’ve been exposed to the virus. ”
Pfizer genuinely the only drugmaker hoping to develop a prophylactic treatment for COVID exposure (especially since variants raise the possibility that vaccinations just might not have to get enough). Merck and Swiss rival Roche have been racing to develop an easy-to-administer antiviral pill of their own – therefore the clock is ticking pertaining to Pfizer.
Reuters explains that the mid-to-late-stage study will certainly test the Pfizer drug’s – known as PF-07321332 capability to prevent COVID symptoms in up to 2, 660 healthful adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID infection.
The particular drug, designed to block the game of a key enzyme necessary for the coronavirus to grow inside the human body, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
Currently, Gilead’s much-hyped but not-all-that-effective IV drug remdesivir could be the only approved antiviral treatment for COVID in the US. Several antibody cocktails have also been widely tested and trials are ongoing – including Merck and partner Ridgeback Biotherapeutics, which recently launched a late-stage trial for experimental COVID prophylactic, molnupiravir.
In the mean period, concerned people should keep an eye out for almost any new information about Ivermectin – if you can find it.